A detailed history of Russell Investments Group, Ltd. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 50 shares of CRSP stock, worth $2,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Previous 250 80.0%
Holding current value
$2,036
Previous $13,000 84.62%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$44.62 - $62.75 $8,924 - $12,550
-200 Reduced 80.0%
50 $2,000
Q2 2024

Aug 08, 2024

BUY
$51.17 - $68.18 $12,792 - $17,045
250 New
250 $13,000
Q2 2023

Aug 10, 2023

BUY
$43.47 - $67.77 $68,595 - $106,941
1,578 Added 13150.0%
1,590 $89,000
Q1 2023

May 09, 2023

BUY
$41.0 - $56.12 $492 - $673
12 New
12 $0
Q2 2022

Jul 29, 2022

SELL
$43.23 - $73.83 $68,130 - $116,356
-1,576 Closed
0 $0
Q1 2022

May 05, 2022

SELL
$53.19 - $79.24 $22,552 - $33,597
-424 Reduced 21.2%
1,576 $98,000
Q4 2021

Jan 21, 2022

SELL
$70.09 - $111.29 $133,171 - $211,451
-1,900 Reduced 48.72%
2,000 $151,000
Q3 2021

Nov 08, 2021

BUY
$110.2 - $156.64 $429,780 - $610,896
3,900 New
3,900 $436,000
Q4 2020

Feb 08, 2021

SELL
$79.67 - $173.23 $50,431 - $109,654
-633 Closed
0 $0
Q3 2020

Nov 09, 2020

SELL
$78.5 - $100.64 $68,687 - $88,060
-875 Reduced 58.02%
633 $53,000
Q2 2020

Aug 05, 2020

SELL
$38.5 - $76.05 $205,936 - $406,791
-5,349 Reduced 78.01%
1,508 $113,000
Q1 2020

May 06, 2020

BUY
$33.68 - $62.53 $230,943 - $428,768
6,857 New
6,857 $293,000
Q1 2018

May 11, 2018

SELL
$23.52 - $58.17 $2.38 Million - $5.89 Million
-101,188 Closed
0 $0
Q4 2017

Feb 06, 2018

BUY
$16.95 - $23.48 $1.72 Million - $2.38 Million
101,188
101,188 $2.15 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.18B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.